0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > FGF R3 (IIIc)

FGF R3 (IIIc)

Brief Information

Name:Fibroblast growth factor receptor 3
Target Synonym:Fibroblast Growth Factor Receptor 3-S,EC:2.7.10.1,EC 2.7.10,JTK4,CD333,FGFR3,Fibroblast Growth Factor Receptor 3,FGFR-3,Fibroblast Growth Factor Receptor 3 Variant 4,Achondroplasia, Thanatophoric Dwarfism,Hydroxyaryl-Protein Kinase,Tyrosine Kinase JTK4,CD333 Antigen,EC 2.7.10.1,HSFGFR3EX,CEK2,ACH,Receptor, Fibroblast Growth Factor, Type 3
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Approved

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
FGC-H5256 Human Human FGF R3 (IIIc) / FGF R3C / CD333 Protein, Fc Tag (MALS verified)
FGC-H5256-structure
FGC-H5256-sds
ACRO Quality

Part of Bioactivity data

FGC-H5256-SPR
 FGF R3 (IIIc) SPR

Human FGF R3 (IIIc), Fc Tag immobilized (Cat. No. FGC-H5256) on CM5 Chip can bind Human FGF acidic, Tag Free (Cat. No. AFF-H4116) with an affinity constant of 0.44 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

FGC-H5256-SPR
 FGF R3 (IIIc) SPR

Human FGF R3 (IIIc), Fc Tag (Cat. No. FGC-H5256) immobilized on CM5 Chip can bind Human FGF-9, Fc Tag (Cat. No. FG9-H4267) with an affinity constant of 10.5 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

FGF R3 (IIIc),FGF R3C,CD333

Background

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Carcinoma, Non-Small-Cell Lung Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Sarcoma, Alveolar Soft Part; Bile Duct Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Hepatic Insufficiency; Bone Neoplasms; Urologic Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Medullary thyroid cancer (MTC); Gallbladder Neoplasms; Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Osteoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Leiomyosarcoma; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Nasopharyngeal Carcinoma Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Thyroid Neoplasms Eisai Inc 2015-02-13 Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 United States Cholangiocarcinoma Incyte Corp 2020-04-17 Multiple Myeloma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Breast Neoplasms; Bone Marrow Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma United States Carcinoma, Renal Cell; Sarcoma Novartis Pharma Ag 2009-10-19 Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a Details
Erdafitinib G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Carcinoma, Non-Small-Cell Lung Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Sarcoma, Alveolar Soft Part; Bile Duct Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Hepatic Insufficiency; Bone Neoplasms; Urologic Neoplasms; Fallopian Tube Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Medullary thyroid cancer (MTC); Gallbladder Neoplasms; Glioma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Osteoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Leiomyosarcoma; Solid tumours; Drug-Related Side Effects and Adverse Reactions; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Lung Diseases, Interstitial; Liver Diseases; Sarcoma; Nasopharyngeal Carcinoma Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Thyroid Neoplasms Eisai Inc 2015-02-13 Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef United States Idiopathic Pulmonary Fibrosis Boehringer Ingelheim Gmbh 2014-10-15 Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Adenocarcinoma, Clear Cell; systemic sclerosis-associated interstitial lung disease; Colorectal Neoplasms; Peritoneal Neoplasms; Gliosarcoma; Hepatic Insufficiency; Astrocytoma; Genital Neoplasms, Female; Silicosis; Sarcoma; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Appendiceal Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Endometrioid; Scleroderma, Systemic; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Rejection of lung transplantation; Carcinoma, Renal Cell; Radiation Pneumonitis; Esophageal Neoplasms; Carcinoid Tumor; Endometrial Stromal Tumors; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Glioblastoma; Colonic Neoplasms; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Oligodendroglioma; Multiple Myeloma; Mesothelioma; Asbestosis; Neuroendocrine Tumors Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 United States Cholangiocarcinoma Incyte Corp 2020-04-17 Multiple Myeloma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Glioma; Lung Neoplasms; Lymphoma; Colitis, Ulcerative; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Breast Neoplasms; Bone Marrow Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Myeloproliferative Disorders; Carcinoma; Carcinoma, Renal Cell; Stomach Neoplasms; Biliary Tract Neoplasms; Solid tumours Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma United States Carcinoma, Renal Cell; Sarcoma Novartis Pharma Ag 2009-10-19 Uterine Cervical Diseases; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Neoplasms; Choriocarcinoma; Lymphoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Mucoepidermoid; Gliosarcoma; Genital Neoplasms, Female; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Brain Neoplasms; Urethral Neoplasms; Medullary thyroid cancer (MTC); Chondrosarcoma, Extraskeletal Myxoid; Prostatic Neoplasms; Osteosarcoma; Neuroblastoma; Sarcoma; Breast Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Neoplasm Metastasis; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Gastrointestinal Neoplasms; Paraganglioma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Melanoma; Gastrinoma; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Carcinoma, Embryonal; Germinoma; Glioma; Carcinoma, Neuroendocrine; Epistaxis; Carcinoma, Ovarian Epithelial; Neoplasms; Squamous Cell Carcinoma of Head a Details
Erdafitinib G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lucitanib S-80881; AL-3810; CO-3810; E-3810; S-80881-2 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Rogaratinib BAY-1163877 Phase 3 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Fexagratinib AZD4547; AZD-4547; ABSK-091; ABSK091 Phase 3 Clinical Astrazeneca Plc Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms Details
Infigratinib BGJ-398; NVP-BGJ398 Phase 3 Clinical Novartis Pharma Ag Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours Details
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Details
SC-0011 SC-0011 Phase 3 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
AUR-109 ODM-203; AUR-109 Phase 2 Clinical Orion Corp Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
HH185 3D-185; 3-D185; HH-185; 3D185 Phase 2 Clinical ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc Solid tumours; Cholangiocarcinoma Details
TYRA-300 TYRA300 Phase 2 Clinical Tyra Biosciences Inc Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms Details
SAR-442501 SAR-442501 Phase 2 Clinical Sanofi Osteochondrodysplasias; Achondroplasia Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Medipharma Ltd Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
Sprifermin rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 Phase 2 Clinical Zymogenetics Inc Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
Recifercept PF-07256472; TA-46 Phase 1 Clinical Pfizer Inc Achondroplasia Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
TYRA-200 TYRA200; TYRA-200 Phase 1 Clinical Tyra Biosciences Inc Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms Details
Resigratinib KIN-3248; KIN-003 Phase 1 Clinical Kinnate Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma Details
TYRA-300-B01 TYRA-300-B01 Phase 1 Clinical Tyra Biosciences Inc Details
LOXO-435 LOXO-435 Phase 1 Clinical Eli Lilly And Company Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Ureteral Neoplasms; Neoplasm Metastasis Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
ABSK-121 ABSK121-NX; ABSK121 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
ABSK-061 ABSK061 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
LY-2874455 LY-2874455 Phase 1 Clinical Eli Lilly And Company Neoplasms; Leukemia, Myeloid, Acute Details
CPL-304110 CPL-304110; CPL-304-110 Phase 1 Clinical Celon Pharma Sa Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
Lucitanib S-80881; AL-3810; CO-3810; E-3810; S-80881-2 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Rogaratinib BAY-1163877 Phase 3 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Fexagratinib AZD4547; AZD-4547; ABSK-091; ABSK091 Phase 3 Clinical Astrazeneca Plc Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Urinary Bladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms Details
Infigratinib BGJ-398; NVP-BGJ398 Phase 3 Clinical Novartis Pharma Ag Papillomavirus Infections; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gastrointestinal Stromal Tumors; Breast Neoplasms; Cholangiocarcinoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Glioblastoma; Biliary Tract Neoplasms; Neoplasms; Achondroplasia; Nasopharyngeal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours Details
Efruxifermin AKR-001; AMG-876; EFX; Fc-FGF21(RGE) Phase 3 Clinical Amgen Inc Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus Details
SC-0011 SC-0011 Phase 3 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
AUR-109 ODM-203; AUR-109 Phase 2 Clinical Orion Corp Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
HH185 3D-185; 3-D185; HH-185; 3D185 Phase 2 Clinical ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc Solid tumours; Cholangiocarcinoma Details
TYRA-300 TYRA300 Phase 2 Clinical Tyra Biosciences Inc Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms Details
SAR-442501 SAR-442501 Phase 2 Clinical Sanofi Osteochondrodysplasias; Achondroplasia Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Medipharma Ltd Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
Sprifermin rhFGF-18; trFGF-18; FGF-18; zFGF-5; Zfgf5; AS-902330 Phase 2 Clinical Zymogenetics Inc Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
Recifercept PF-07256472; TA-46 Phase 1 Clinical Pfizer Inc Achondroplasia Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
TYRA-200 TYRA200; TYRA-200 Phase 1 Clinical Tyra Biosciences Inc Biliary Tract Neoplasms; Solid tumours; Cholangiocarcinoma; Bile Duct Neoplasms Details
Resigratinib KIN-3248; KIN-003 Phase 1 Clinical Kinnate Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma Details
TYRA-300-B01 TYRA-300-B01 Phase 1 Clinical Tyra Biosciences Inc Details
LOXO-435 LOXO-435 Phase 1 Clinical Eli Lilly And Company Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Ureteral Neoplasms; Neoplasm Metastasis Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
ABSK-121 ABSK121-NX; ABSK121 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
ABSK-061 ABSK061 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
LY-2874455 LY-2874455 Phase 1 Clinical Eli Lilly And Company Neoplasms; Leukemia, Myeloid, Acute Details
CPL-304110 CPL-304110; CPL-304-110 Phase 1 Clinical Celon Pharma Sa Stomach Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Cholangiocarcinoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop

Laisser un message